Could a common Weight-Loss drug help hormone therapy work better for young women with endometrial cancer?
NCT ID NCT07714070
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone receptor levels. Participants receive either progestin alone or progestin plus orlistat for 3 months, then are followed for 24 months. The main goal is to see if orlistat boosts progesterone receptor expression and leads to complete disease reversal, helping preserve fertility.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- orlistat combined with progestin (medroxyprogesterone acetate or megestrol acetate)
- What this could lead to
- If it works, this could offer a fertility-sparing treatment option for young women with endometrial cancer who do not respond well to standard hormone therapy.
- What could go wrong
- This is a small, early-phase trial with only 48 participants, so results may not apply to everyone. Orlistat can cause gastrointestinal side effects, and the combination may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL ENDOMETRIAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A safer first cut? trial tests two laparoscopic entry points for endometrial cancer surgery
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New imaging tool could help surgeons detect hidden cancer cells during surgery
- Could a simple diet replace an enema before endometrial cancer surgery?
- Proton beam therapy plus chemo aims to improve Post-Surgery treatment for advanced endometrial cancer
- Scientists probe hidden clues to immunotherapy success in endometrial cancer